These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19264351)

  • 21. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
    Goff BA; Holmberg LA; Veljovich D; Kurland BF;
    Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
    Matulonis U; Berlin S; Lee H; Whalen C; Obermayer E; Penson R; Liu J; Campos S; Krasner C; Horowitz N
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):417-23. PubMed ID: 26119093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
    Piura B; Meirovitz M
    Eur J Gynaecol Oncol; 2005; 26(4):386-90. PubMed ID: 16122184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
    Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
    Konner J; Schilder RJ; DeRosa FA; Gerst SR; Tew WP; Sabbatini PJ; Hensley ML; Spriggs DR; Aghajanian CA
    Gynecol Oncol; 2008 Aug; 110(2):140-5. PubMed ID: 18554700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
    Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
    Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
    Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
    Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.
    Sehouli J; Alvarez AM; Manouchehrpour S; Ghatage P; Szczylik C; Zimmermann A; Bauknecht T; Look KY; Oskay-Öezcelik G
    Gynecol Oncol; 2012 Feb; 124(2):205-9. PubMed ID: 22044606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
    Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM
    Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
    Markman M; Glass T; Smith HO; Hatch KD; Weiss GR; Taylor SA; Goodwin JW; Alberts DS
    Gynecol Oncol; 2003 Mar; 88(3):282-8. PubMed ID: 12648576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
    Escobar PF; Markman M; Rose P; Zanotti K; Webster K; Belinson J
    Gynecol Oncol; 2004 Jan; 92(1):192-6. PubMed ID: 14751157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
    Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
    Pautier P; Joly F; Kerbrat P; Bougnoux P; Fumoleau P; Petit T; Rixe O; Ringeisen F; Carrasco AT; Lhommé C
    Gynecol Oncol; 2010 Feb; 116(2):157-62. PubMed ID: 20109725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.